Evidence map›Paper›PMID 25932028›Full record

ArticleFrontiers in immunology2015

Effects of immunosuppressive drugs on viability and susceptibility of adipose- and bone marrow-derived mesenchymal stem cells.

Wakako Tsuji, Jonas T Schnider, Meghan M McLaughlin, Riccardo Schweizer, Wensheng Zhang, Mario G Solari, J Peter Rubin, Kacey G Marra, Jan A Plock, Vijay S Gorantla

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Annals of translational medicine · 2020
    Article
  12. Article
  13. Review
  14. Influence of the Type of Delivery, Use of Oxytocin, and Maternal Age onOxidative medicine and cellular longevity · 2019
    Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Wakako TsujiDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Surgery, Shiga Medical Center for Adults , Moriyama , Japan.
Jonas T SchniderDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA.
Meghan M McLaughlinDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA.
Riccardo SchweizerDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Plastic Surgery and Hand Surgery, University Hospital Zurich , Zurich , Switzerland.
Wensheng ZhangDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA.
Mario G SolariDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA.
J Peter RubinDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Bioengineering, University of Pittsburgh , Pittsburgh, PA , USA.
Kacey G MarraDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Bioengineering, University of Pittsburgh , Pittsburgh, PA , USA.
Jan A PlockDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; Department of Plastic Surgery and Hand Surgery, University Hospital Zurich , Zurich , Switzerland.
Vijay S GorantlaDepartment of Plastic Surgery, University of Pittsburgh , Pittsburgh, PA , USA ; McGowan Institute for Regenerative Medicine, University of Pittsburgh , Pittsburgh, PA , USA.
University of Pittsburgh · USMcGowan Institute for Regenerative Medicine · USUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunomodulatory potential of cell therapies using adipose-derived stem cells (ASCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) has been studied in vascularized composite allotransplantation (VCA). Most cell therapy-based experimental and clinical protocols integrate some degree of recipient conditioning/induction with antibodies or other immunosuppressive agents. We investigated the susceptibility of ASCs and BM-MSCs to anti-lymphocyte serum (ALS) and tacrolimus. Rat ASCs and BM-MSCs were exposed to varying concentrations of tacrolimus and ALS in vitro. Serum from ALS-treated animals was added to cell cultures. Viability, susceptibility, and cytotoxicity parameters were evaluated. ALS inhibited ASC and BM-MSC viability and susceptibility in vitro in a dose-dependent manner. ASCs were more susceptible to both ALS and tacrolimus than BM-MSCs. Trypsinized and adherent ASCs were significantly smaller than BM-MSCs. This is the first report on the viability and susceptibility characteristics of BM-MSCs or ASCs to collateral effects of ALS and tacrolimus. These in vitro insights may impact choice of cell type as well as concomitant conditioning agents and the logistical coordination of the timing, dosing, and frequency of drug or cell therapy in solid organ transplantation or VCA protocols.

Indexed as

adipose-derived stem cellsanti-lymphocyte serumbone marrow-derived stem cellscell sizeimmunomodulationsusceptibilitytacrolimusviability

Identifiers

PMID25932028
PMCPMC4399413
OpenAlexW2060070197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.